Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADME and Bioavailability of PF-07976016 in Healthy Men
NCT07015918Phase 1Completed
- Sponsor
- Pfizer
- Start
- Jun 2025
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PF-07976016 in obesity, sponsored by Pfizer. Primary endpoint: Total recovery of radioactivity expressed as a percent of total oral radioactive dose administered up to 21 days. Started Jun 2025; status: completed.
02
Drugs
PF-07976016
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07015918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07015918.